Actively Recruiting
PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Led by Peking University Third Hospital · Updated on 2025-01-24
20
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluate the safety and efficacy of PD-1 antibody Carilizumab combined with apatinib for the conversion therapy of unresectable stage III and IV dMMR gastric cancer.
CONDITIONS
Official Title
PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any gender
- Histologically confirmed unresectable stage III or IV dMMR gastric adenocarcinoma or gastroesophageal junction adenocarcinoma
- Gastric cancer with potential for conversion therapy, including single organ metastasis, lymph node metastasis, localized peritoneal metastasis, or invasion of surrounding organs
- No prior surgery, radiation therapy, or immunotherapy for gastric cancer or metastases
- ECOG performance status of 0 or 1
- Expected survival of at least 3 months
- Normal main organ functions without severe abnormalities
- Normal blood clotting function and no active bleeding or thrombotic diseases
- At least 2 weeks since last use of traditional Chinese medicine or immunomodulators with anti-tumor drugs
- Use of medically approved contraception during and for 180 days after treatment for females of childbearing age and males with partners of childbearing age
- Negative serum HCG test within 72 hours before enrollment for females of childbearing age who are not surgically sterilized
- Willingness to participate and signed informed consent form
You will not qualify if you...
- Diagnosis of other malignant tumors within 5 years except certain treated cancers
- Active or history of autoimmune diseases requiring medical intervention
- Congenital or acquired immune deficiency including HIV or active hepatitis B or C infections
- Use of immunosuppressive drugs within 14 days before starting treatment (except low-dose corticosteroids)
- Vaccination with live attenuated vaccine within 4 weeks before or planned during the study
- Uncontrolled hypertension despite medication
- Unstable heart conditions, including recent heart attack or severe heart failure
- Lung diseases affecting pulmonary function or suspected drug-related lung toxicity
- Active pulmonary tuberculosis
- Severe infections requiring intravenous antibiotics within 4 weeks before treatment
- History of allogeneic organ or stem cell transplantation
- Known allergies to study drug components
- Other severe, acute, or chronic illnesses increasing risks or interfering with study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University third hospital
Beijing, China
Actively Recruiting
Research Team
Y
Yanhong Yao
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here